Methods and compositions for treating meibomian gland dysfunction, dry eye disease, and related disorders

Knowledge Center

Patent / Apr 28, 2022

Methods and compositions for treating meibomian gland dysfunction, dry eye disease, and related disorders

Authors:

Carla Vozone
Mohammad Salman
George Magrath
Courtney Smith

Source:

US 20220125829

The invention provides methods, compositions, and kits containing a pharmaceutical composition, for treating meibomian gland dysfunction, dry eye disease, and related disorders.

Also in the Knowledge Center

/ Jan 01, 2012

A hybrid approach to reach stringent low genotoxic impurity contents in active pharmaceutical ingredients: Combining molecularly imprinted polymers and organic solvent nanofiltration for removal of 1,3-diisopropylurea

Scientific Article

View

/ Jan 01, 1998

Pharmacokinetics, protein binding, and metabolic profile of 3H-icometasone enbutate following intravenous, oral, and intratracheal administrations to Sprague-Dawley rats

Scientific Article

View

��ɫAV

Browser not supported

Knowledge Center

Methods and compositions for treating meibomian gland dysfunction, dry eye disease, and related disorders

Also in the Knowledge Center

A hybrid approach to reach stringent low genotoxic impurity contents in active pharmaceutical ingredients: Combining molecularly imprinted polymers and organic solvent nanofiltration for removal of 1,3-diisopropylurea

Pharmacokinetics, protein binding, and metabolic profile of 3H-icometasone enbutate following intravenous, oral, and intratracheal administrations to Sprague-Dawley rats

��ɫAV

Browser not supported

Knowledge Center

Methods and compositions for treating meibomian gland dysfunction, dry eye disease, and related disorders

Also in the Knowledge Center

A hybrid approach to reach stringent low genotoxic impurity contents in active pharmaceutical ingredients: Combining molecularly imprinted polymers and organic solvent nanofiltration for removal of 1,3-diisopropylurea

Pharmacokinetics, protein binding, and metabolic profile of 3H-icometasone enbutate following intravenous, oral, and intratracheal administrations to Sprague-Dawley rats

Related Content

��ɫAV and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions

Formulation

��ɫAV and Zerion Pharma create joint venture to further expand use of Dispersome® technology